Evidence map›Paper›PMID 38746878›Full record

ArticleACS medicinal chemistry letters2024

Identification of Selective Imidazopyridine CSF1R Inhibitors.

John L Kane, Gary Asmussen, Joseph Batchelor, Mandy Cromwell, Malika Fezoui, Maria Fitzgerald, Barret Giese, Tatiana Gladysheva, Stephanie Holley, Kelly Keefe and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

John L KaneIntegrated Drug Discovery, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.ORCID https://orcid.org/0009-0006-6971-6797
Gary AsmussenIntegrated Drug Discovery, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Joseph BatchelorIntegrated Drug Discovery, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Mandy CromwellRare and Neurologic Disease Research, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Malika FezouiRare and Neurologic Disease Research, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Maria FitzgeraldDrug Metabolism and Pharmacokinetics, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.ORCID https://orcid.org/0000-0003-0099-0465
Barret GieseIntegrated Drug Discovery, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Tatiana GladyshevaIntegrated Drug Discovery, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Stephanie HolleyIntegrated Drug Discovery, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Kelly KeefeRare and Neurologic Disease Research, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Michael KotheIntegrated Drug Discovery, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Becky LamIntegrated Drug Discovery, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Sungtaek LimIntegrated Drug Discovery, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Jinyu LiuIntegrated Drug Discovery, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Liang MaIntegrated Drug Discovery, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Markus MetzIntegrated Drug Discovery, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Andrew A ScholteIntegrated Drug Discovery, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Patrick ShumIntegrated Drug Discovery, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
LinLi WeiIntegrated Drug Discovery, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Lisa WoodworthRare and Neurologic Disease Research, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Andrea EdlingRare and Neurologic Disease Research, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colony stimulating factor-1 receptor (CSF1R or c-FMS), a class III receptor tyrosine kinase expressed on members of the mononuclear phagocyte system (MPS), plays a key role in the proper functioning of macrophages, microglia, and related cells. Aberrant signaling through CSF1R has been associated with a variety of disease states, including cancer, inflammation, and neurodegeneration. In this Letter, we detail our efforts to develop novel CSF1R inhibitors. Drawing on previously described compounds, including GW2580 (

Identifiers

PMID38746878
PMCPMC11089549

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.